GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: Gilead is a biopharmaceutical company focused on the discovery, development, and commercialization of antivirals, antibacterials, and antifungals. Key marketed products include Viread and Emtriva (HIV), Hepsera (Hepatitis B), AmBisome (fungal infections), and DaunoXome (Kaposi's Sarcoma). The company also earns royalties on Tamiflu (influenza) marketed by Roche.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 50% quarter-over-quarter and 88% year-over-year (nine-month period). This was driven primarily by a 61% increase in product sales, led by Viread (HIV treatment), which grew from $68.9 million to $115.4 million in the third quarter.
• Profitability Volatility: While the third quarter of 2003 was profitable ($73.1 million net income), the nine-month period resulted in a net loss of $264.6 million. This loss is primarily attributable to a one-time non-cash charge of $488.6 million for in-process research and development (IPR&D) related to the acquisition of Triangle Pharmaceuticals, Inc. in January 2003.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose significantly (50% in Q3, 39% in 9 months) due to expanded sales forces and marketing for Viread, Hepsera, and Emtriva. R&D expenses increased 12% for the nine months, driven by Triangle-related clinical trials and a new license from Chiron.
• Liquidity: Cash and cash equivalents decreased from $616.9 million at year-end 2002 to $103.3 million at September 30, 2003. This reduction was due to the $375.5 million net cash outflow for the Triangle acquisition and a $123.0 million purchase of the company's Foster City campus.

Guidance, Outlook, and Risks

• Revenue Guidance: Management expects full-year 2003 Viread sales to range between $550 million and $570 million. Full-year AmBisome sales are expected to be flat at $180 million to $185 million.
• Expense Outlook: Full-year 2003 R&D expenses are projected at $155 million to $160 million. SG&A expenses are projected at $240 million to $250 million.
• Tax Outlook: The effective tax rate is expected to remain in the mid-single digits for the remainder of 2003, increasing to approximately 30% in 2004.
• Key Risks:
  • Product Dependence: Significant reliance on Viread and AmBisome for operating income.
  • Regulatory & Safety: Potential for new safety issues (e.g., kidney toxicity warnings for Viread) and regulatory actions (e.g., FDA warning on promotional practices).
  • Development Uncertainty: Risks associated with the commercialization of Triangle assets (Emtriva, fixed-dose combinations) and the possibility of discontinuing programs if commercialization proves difficult.
  • Foreign Currency: Significant exposure to foreign currency fluctuations, particularly the Euro, which impacts revenue and gross margins.

Investor Verification Checklist

• Triangle Acquisition Integration: Verify the progress of Emtriva commercialization and the status of the fixed-dose combination (Viread/Emtriva) regulatory approval, as these were the primary drivers of the $488.6 million IPR&D charge.
• Wholesaler Inventory Levels: Confirm current inventory levels at major U.S. distributors (AmerisourceBergen, McKesson, Cardinal Health), as a recent inventory reduction negatively impacted Q3 Viread sales by an estimated $33–$37 million.
• Regulatory Compliance: Monitor the status of the FDA warning issued in August 2003 regarding Viread promotional practices and any resulting penalties or restrictions.
• European Reimbursement: Assess the impact of government reimbursement delays in European markets (specifically Greece, Spain, Portugal, and Italy) on accounts receivable collection.
• Debt Structure: Review the terms of the $595 million in convertible debt ($345M senior, $250M subordinated) and potential dilution upon conversion.